Clinical trials: Anticoagulant Drugs
Anticoagulants and Bleeding Disorders
DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic
New/direct oral anticoagulants (NOAC/DOAC), like apixaban and rivaroxaban, are an interesting alternative to unfractionated or low molecular weight heparin relayed by oral anti-vitamin K anticoagulants (VKA) for the treatment of…
- Trial name
- DAPHNE (NCT03112525)
- Testing
- CYP3A4/5 and P-gp phenotyping, CYP3A4/5 and P-gp genotyping
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- University Hospital, Geneva
Coronary Artery Disease
Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI
The purpose of this study is to determine if it is feasible and safe to use the REG1 Anticoagulation System instead of unfractionated heparin during percutaneous coronary intervention (PCI) in subjects with coronary artery…
- Trial name
- REVERSAL-PCI (NCT00715455)
- Testing
- REG1, Unfractionated Heparin
- Where
- 6 sites in United States, Argentina
- Volunteers
- 26 people
- Sponsor
- Regado Biosciences, Inc.
Extracorporeal Membrane Oxygenation Complication, Thrombosis
D-dimer to Improve Anticoagulation Outcome During ECMO loNg-term supporteD
This was a prospective, cohort study.
- Conditions
- Extracorporeal Membrane Oxygenation Complication, Thrombosis, Hemorrhage, Heparin Overdose
- Trial name
- DIAMOND (NCT03261284)
- Testing
- D-dimer-guided adjustment stratege, Thepeautic-heparin therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Wuhan Asia Heart Hospital
Hemostasis
Choice of Anticoagulant for Primary Hemostasis Studies With PFA200® (Platelet Function Analyser)
The PFA (platelet function analysis) test is prescribed for the exploration of primary hemostasis and the study of platelet-willebrand factor interaction.
- Trial name
- BAPAPFA (NCT06753838)
- Testing
- Sampling of 3 additional BAPA tubes
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Bleeding After GI Endoscopy
Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Controlled Trial
Background： Colonoscopy can detect colon polyps and perform excision to the polyps to prevent colon cancer. However, delayed polypectomy bleeding is one of the complications to be noticed, which has an occurrence rate of about…
- Trial name
- NCT07257926
- Testing
- Sucralfate, Clip
- Volunteers
- 160 people
- Sponsor
- National Cheng-Kung University Hospital
Cirrhosis, HCC - Hepatocellular Carcinoma
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
- Conditions
- Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis
- Trial name
- NCT07132515
- Testing
- Enoxaparin, warfarrin, or apixaban
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Percutaneous Coronary Intervention
Registry of the Combination of Antiplatelet Agents and Anticoagulant in Atrial Fibrillation Patients With a CHA2DS2VASc Score >1 Undergoing Percutaneous Coronary Interventions
Patients undergoing percutaneous coronary intervention (PCI) with stent implantation and requiring chronic anticoagulation for atrial fibrillation (AF) with a CHA2DS2-VASc >1 are required to receive triple antithrombotic therapy…
- Trial name
- NCT03012906
- Testing
- the prevalence of ischemic events
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Covid19
Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents…
- Trial name
- CORONA (NCT04518735)
- Testing
- Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
- Where
- Spain
- Volunteers
- 1,707 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Enoxaparin
Pharmacodynamic Equivalence of Ovine Enoxaparin to Lovenox®
This study is designed as a randomized, open-label, 2-way cross-over, single dose study with at least 7 days wash-out period. The objective of this study is to demonstrate the pharmacodynamic / pharmacokinetic equivalence of…
- Trial name
- NCT04402762
- Testing
- Ovine Enoxaparin, Enoxaparin Prefilled Syringe [Lovenox]
- Where
- Indonesia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Atrial Fibrillation, Thrombus Due to Heart Valve Prosthesis
The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT
Warfarin is an anticoagulant medication that is highly effective at preventing clotting disorders but which has a narrow therapeutic window.
- Conditions
- Atrial Fibrillation, Thrombus Due to Heart Valve Prosthesis, Deep Venous Thrombosis, Thromboembolism
- Trial name
- NCT02376803
- Testing
- Warfarin
- Where
- 2 sites in Canada
- Volunteers
- 217 people
- Sponsor
- University of Alberta
Ischemic Stroke, Atrial Fibrillation
TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation
This study will compare early with late start of treatment with Non-vitamin K oral anticoagulation (NOAC) in adult patients with acute ischemic stroke and atrial fibrillation; it is a registry-based randomized clinical trial…
- Trial name
- NCT02961348
- Testing
- Early start of NOAC, Late start of NOAC
- Where
- 36 sites in Sweden
- Volunteers
- 888 people
- Sponsor
- Uppsala University
Stable Angina, Unstable Angina
COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
Prospective, multi-centre, randomized, open-label, parallel comparisons to evaluate the incidence of bleedings (COSTA-Bleed) and the incidence of ischemic and bleeding events (COSTA-Outcome) following a therapy with the abluminal…
- Conditions
- Stable Angina, Unstable Angina, STEMI, NSTEMI
- Trial name
- COSTA (NCT02723981)
- Testing
- COMBO-Stent, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran, Any drug eluting stent oder bare metal sent
- Where
- 10 sites in Germany
- Sponsor
- IHF GmbH - Institut für Herzinfarktforschung
Atrial Fibrillations, Heart Valve Prostheses
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with…
- Conditions
- Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes, Coronary Artery Diseases
- Trial name
- WOEST 2 (NCT02635230)
- Testing
- Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 2,200 people
- Sponsor
- R&D Cardiologie
SARS-COV-2
Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant
SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection called COVID19. A large proportion of patients, in particular in severe forms, present with thrombotic manifestations (DVT, EP, stroke…
- Trial name
- LA-COVID (NCT05075928)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Oral Antiplatele, Anticoagulant Drugs
Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation
This observational study aims to assess the effect of oral antiplatelet or anticoagulant drugs on key postoperative outcomes in patients with lower extremity varicose veins who have undergone radiofrequency ablation.
- Conditions
- Oral Antiplatele, Anticoagulant Drugs, Lower Extremity Varicose Veins, Radiofrequency Ablation
- Trial name
- NCT07208695
- Testing
- Antiplatelet or Anticoagulant Drugs
- Volunteers
- 40 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Non-valvular Atrial Fibrillation
Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program
This study is multicentric, single-blind, and interventional with a randomization into two parallel arm, between a standard of care information and an additional information of the patient, with a 12 month follow up.
- Trial name
- MONACO (NCT02422602)
- Testing
- Xarelto, Experimental: Personalized information intervention
- Where
- France
- Volunteers
- 196 people
- Sponsor
- University Hospital, Montpellier
Thrombus of Left Ventricle
Cohort of Patients With Left Ventricular Thrombus: Management and Outcomes in the Direct Oral Anticoagulants Era
The investigators' primary objective is to assess whether a difference in the occurrence of bleeding events exist between patients with LVT treated with DOACs as compared to those treated with VKAs.
- Trial name
- LV-Thrombus (NCT05028777)
- Where
- Switzerland
- Volunteers
- 550 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Recurrent Venous Thromboembolism, Idiopathic Deep Vein Thrombosis
Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)
In a French multicenter double blind randomized controlled trial, the main objective is to demonstrate that, after 6 months of oral anticoagulation for a first episode of idiopathic proximal deep vein thrombosis, 18 months of…
- Trial name
- PADIS TVP (NCT00740493)
- Testing
- warfarin
- Where
- 14 sites in France
- Volunteers
- 104 people
- Sponsor
- University Hospital, Brest
Atrial Fibrillation, Cardioembolic Stroke
Long-term Results of Percutaneous Left Atrial Closure at Brest University Hospital (CLAPOT)
Atrial Fibrillation represents an important risk of cardioembolic stroke. In more than 90% of cases, thrombus originate in the left atrial appendage.
- Conditions
- Atrial Fibrillation, Cardioembolic Stroke, Left Atrial Appendage Thrombosis, Anticoagulant-induced Bleeding
- Trial name
- CLAPOT (NCT06232278)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Brest
Peripheral Arterial Disease
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
- Trial name
- NCT05009862
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 81Mg Ec Tab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University Medical Center